Literature DB >> 25124559

Review of the molecular pathogenesis of osteosarcoma.

Jin-Peng He1, Yun Hao, Xiao-Lin Wang, Xiao-Jin Yang, Jing-Fan Shao, Feng-Jin Guo, Jie-Xiong Feng.   

Abstract

Treating the osteosarcoma (OSA) remains a challenge. Current strategies focus on the primary tumor and have limited efficacy for metastatic OSA. A better understanding of the OSA pathogenesis may provide a rational basis for innovative treatment strategies especially for metastases. The aim of this review is to give an overview of the molecular mechanisms of OSA tumorigenesis, OSA cell proliferation, apoptosis, migration, and chemotherapy resistance, and how improved understanding might contribute to designing a better treatment target for OSA.

Entities:  

Mesh:

Year:  2014        PMID: 25124559     DOI: 10.7314/apjcp.2014.15.15.5967

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  60 in total

1.  Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma.

Authors:  Yu-Xin Zhao; Yi-Sheng Wang; Qi-Qing Cai; Jia-Qiang Wang; Wei-Tao Yao
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  miR-155 promotes the growth of osteosarcoma in a HBP1-dependent mechanism.

Authors:  Xiaohui Sun; Xiaolin Geng; Jun Zhang; Hongxing Zhao; Ying Liu
Journal:  Mol Cell Biochem       Date:  2015-02-10       Impact factor: 3.396

3.  miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b.

Authors:  Qing Liu; Zhenting Wang; Xiaohua Zhou; Mingying Tang; Wei Tan; Tianshi Sun; Youwen Deng
Journal:  Cell Cycle       Date:  2019-10-10       Impact factor: 4.534

4.  Identification of candidate drugs for the treatment of metastatic osteosarcoma through a subpathway analysis method.

Authors:  Xin Li; Ming-Lan Yan; Qian Yu
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

5.  Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells.

Authors:  Xiwei Liu; Li Min; Hong Duan; Rui Shi; Wenli Zhang; Song Hong; Chongqi Tu
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064

6.  Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.

Authors:  Eric R Molina; Letitia K Chim; Sergio Barrios; Joseph A Ludwig; Antonios G Mikos
Journal:  Tissue Eng Part B Rev       Date:  2020-02-14       Impact factor: 6.389

7.  Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.

Authors:  Yun-Rong Zhu; Han Min; Jian-Feng Fang; Feng Zhou; Xiong-Wei Deng; Yun-Qing Zhang
Journal:  Cancer Biol Ther       Date:  2015-04-14       Impact factor: 4.742

8.  Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.

Authors:  Vasilios Liapis; Agatha Labrinidis; Irene Zinonos; Shelley Hay; Vladimir Ponomarev; Vasilios Panagopoulos; Mark DeNichilo; Wendy Ingman; Gerald J Atkins; David M Findlay; Andrew C W Zannettino; Andreas Evdokiou
Journal:  Cancer Lett       Date:  2014-11-15       Impact factor: 8.679

9.  Elevated circulating macrophage inhibitory cytokine 1 is a biological marker for the diagnosis and prognosis of osteosarcoma.

Authors:  Xianxiang Song; Lijun Tian; Yanqiu Quan; Dan Sun; Linmei Zhang
Journal:  Exp Ther Med       Date:  2018-09-21       Impact factor: 2.447

10.  Necrosis of osteosarcoma cells induces the production and release of high-mobility group box 1 protein.

Authors:  Jiyu Yang; Zhiqiang Ma; Yanlong Wang; Zengkun Wang; Youwei Tian; Yingchao Du; Wei Bian; Yongfu Duan; Jianyu Liu
Journal:  Exp Ther Med       Date:  2017-11-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.